Preparation of 5-(2,6-dideoxy-2-fluoro-α-L-talopyranosyloxy)-6-hydroxynaphtho[2,3-f]quinoline- 7,12-dione (FT-Alz), a new-type, potentially antitumor substance with various biological activities

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 3, 2000, Pages 203-207

  Tsuchiya, Tsutomu ^a   Takagi, Yasushi ^a   Yamada, Hajime ^b  

^a Microbial Chemistry Research Center   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 2' FLUORO 3' HYDROXYDOXORUBICIN 14 PIMELATE; 5 (2,6 DIDEOXY 2 FLUORO ALPHA L TALOPYRANOSYLOXY) 6 HYDROXYNAPHTHO[2,3 F]QUINOLINE 7,12 DIONE; ANTHRAQUINONE DERIVATIVE; BLEOMYCIN; CARBOQUONE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DRUG ANALOG; GLYCOPROTEIN P; MITOMYCIN C; PEPLEOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHEMICAL MODIFICATION; DOSE RESPONSE; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOSIDES; MICE; NAPHTHOQUINONES; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0034614994     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00655-1     Document Type: Article

References (20)

1. Tsuchiya T., Takagi Y., Ok K., Umezawa S., Takeuchi T., Wako N., Umezawa H. J. Antibiot. 39:1986;731.
2. Ok K., Takagi Y., Tsuchiya T., Umezawa S., Umezawa H. Carbohydr. Res. 169:1987;69.
3. Bachur N.R., Gordon S.L., Gee M.V. Cancer Res. 38:1978;1745.
4. Monks T.J., Hanzlik R.P., Cohen G.M., Ross D., Graham D.G. Toxicol. Appl. Pharmacol. 112:1992;2.
5. Auerbach G. J. Chem. Soc. 35:1879;799.
6. Graebe C. Ann. 201:1880;333.
7. Hosoda Y. J. Synth. Org. Chem. Jpn. 9:1951;23.
8. 3′,F 34 Hz, F-2′).
9. Detailed NMR data of 9 will be submitted in a forthcoming article.
10. Yamori T., Matsunaga A., Sato S., Yamazaki K., Komi A., Ishizu K., Mita I., Edatsugi H., Matsuba Y., Takezawa K., Nakanishi O., Kohno H., Nakajima Y., Komatsu H., Andoh T., Tsuruo T. Cancer Res. 59:1999;4042.
11. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Cambell H., Mayo J., Boyd M. J. Natl. Cancer Inst. 83:1991;757.
12. Yamori T. Jpn. J. Cancer Chemother. 24:1997;129.
13. 0)×100=-50 at time t, respectively.
14. Yamori T. Jpn J. Cancer Chemother. 25(Supplement II):1998;373.
15. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Cancer Res. 41:1981;1967.
16. Broxterman H.J., Kuiper C.M., Schuurhuis G.J., Tsuruo T., Pinendo H.M., Lankelma J. Biochem. Pharmacol. 37:1988;2389.
17. Recombinant human topoisomerase IIa purified from the lysates of a recombinant baculovirus-infected H5 insect cells was used.
18. Marini J.C., Miller K.G., Englund P.T. J. Biol. Chem. 255:1980;4976.
19. Tanabe K., Ikegami Y., Ishida R., Andoh T. Cancer Res. 51:1991;4903.
20. Personal communication from Professor Toshiwo Andoh of Soka University.